Institution: | 1. Medicinal Plants Processing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Biochemistry, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran;2. Department of Biochemistry, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;3. Cellular and Molecular Biology Research Center (CMBRC), Health Research Institute, Babol University of Medical Sciences, Babol, Irantab
Department of Clinical Biochemistry, Babol University of Medical Sciences, Babol, Iran;4. Solid Tumor Research Center, Urmia University of Medical Sciences, Urmia, Iran;5. Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;6. Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran |
Abstract: | Inflammatory bowel disease (IBD), as a chronic and recurrent inflammatory disorder, is caused by a dysregulated and aberrant immune response to exposed environmental factors in genetically susceptible individuals. Despite huge efforts in determining the molecular pathogenesis of IBD, an increasing worldwide incidence of IBD has been reported. MicroRNAs (miRNAs) are a set of noncoding RNA molecules that are about 22 nucleotides long, and these molecules are involved in the regulation of the gene expression. By clarifying the important role of miRNAs in a number of diseases, their role was also considered in IBD; numerous studies have been performed on this topic. In this review, we attempt to summarize a number of studies and discuss some of the recent developments in the roles of miRNAs in the pathophysiology, diagnosis, and treatment of IBD. |